

Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003

Page 10 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following items, which are listed on the Substitute Form PTO-1449 attached hereto as **Exhibit B**. Item 1 is a U.S. Patent and item 2 is a U.S. Patent Application Publication. In accordance with 37 C.F.R. §1.98(a)(2), copies of items 1 and 2 are not enclosed herewith. Copies of items 3-26 are enclosed herewith as **Exhibits 1-24**, respectively.

1. U.S. Patent No. 5,008,284 issued to Grover et al. on April 16, 1991;
2. U.S. Patent Application Publication No. 2003-0054418, published March 20, 2003, Bodnar et al;
3. PCT International Publication No. WO 03/090512, published November 6, 2003 (U.S. Serial No. PCT/US03/12768); **(Exhibit 1)**
4. International Search Report issued on August 24, 2004 in connection with corresponding International Application No. PCT/US03/12768, filed April 23, 2002; **(Exhibit 2)**
5. Bonaros et al. (2008), "CCR3- and CXCR4-mediated Interactions Regulate Migration of CD34+ Human Bone Marrow Progenitors to Ischemic Myocardium and Subsequent Tissue Repair." J. Thor. Cardio. Surg., 136(4):1044-1053; **(Exhibit 3)**
6. Chavakis, E. (2006), "IL-8: A New Player in the Homing of Endothelial Progenitor Cells to Ischemic Myocardium." J. Mol. Cell. Cardiol. 40:442-445; **(Exhibit 4)**

Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003

Page 11 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

7. Janeway, et al. (1997), "Immunobiology: The Immune System in Health and Disease." NY: Current Biology Limited. 1:11-12; **(Exhibit 5)**
8. Khachigian, LM, (2000), "Catalytic DNAs as Potential Therapeutic Agents and Sequence-Specific Molecular Tools to Dissect Biological Function." J. of Clin Investigation 106(10):1189-1195; **(Exhibit 6)**
9. Kocher, et al. (2006), "Myocardial Homing and Neovascularization by Human Bone Marrow Angioblasts is Regulated by IL-8/Gro CXC Chemokines." J. Mol. Cell. Cardiol. 40:455-464; **(Exhibit 7)**
10. Lefer, et al. (1991), "Cardioprotective and Endothelial Protective Effects of [Ala-IL8]<sub>77</sub> in a Rabbit Model of Myocardial Ischaemia and Reperfusion." Br. J. Pharmacol. 103:1152-1159; **(Exhibit 8)**
11. Nishiyama, et al. (1999), "Identification of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression." J Biol. Chem. 274(31):21645-21650; **(Exhibit 9)**
12. Pak, J.H. et al. (2002), "An antisense Oligonucleotides to 1-cys Peroxiredoxin Causes Lipid Peroxidation and Apoptosis in Lung Epithelial Cells." J. Bio. Chem., 277(51):49927-49934; **(Exhibit 10)**
13. Park, S. et al. (2000), "Antisense of Human Peroxiredoxin II Enhances Radiation-Induced Cell Death." Clin. Cancer. Research, 6:4915-4920; **(Exhibit 11)**

Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003  
Page 12 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

14. Rinn, et al. (2006), "Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs." PLOS Genetics 2(7):1084-1096; **(Exhibit 12)**
15. UniprotKB/Swiss-Prot P10145 (IL\_8HUMAN),  
www.uniprot/P10145. Last Modified May 26, 2009. Version 120; **(Exhibit 13)**
16. Wang, L. (2000), "ACE Inhibitors and Beta Blockers Equally Attenuate Ischemia-Induced Reduction in Ventricular Fibrillation Threshold." Exp. Clin. Cardiol. 5(2):82-86; **(Exhibit 14)**
17. Xiang et al. 2005, Catalytic Degradation of Vitamin D Up-Regulated Protein 1 mRNA Enhances Cardiomyocytes Survival and Prevents Left Ventricula Remodeling After Myocardial Ischemia." J Biol Chem 280(47):39394-39402; **(Exhibit 15)**
18. March 10, 2006 Official Action issued in connection with corresponding Chinese Patent Application No. 03814715.7; **(Exhibit 16)**
19. April 29, 2008 Official Action issued in connection with corresponding Israeli Patent Application No. 164671; **(Exhibit 17)**
20. November 20, 2008 Final Office Action issued in connection with co-pending U.S. Serial No. 11/234,879; **(Exhibit 18)**
21. December 31, 2008 Office Action issued in connection with co-pending U.S. Serial No. 11/894,555; **(Exhibit 19)**
22. February 12, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/894,555; **(Exhibit 20)**

Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003

Page 13 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

23. March 10, 2009 Office Action issued in connection with co-pending U.S. Serial No. 10/512,518; **(Exhibit 21)**
24. March 13, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/648,769; **(Exhibit 22)**
25. June 12, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/894,581; **(Exhibit 23)** and
26. July 9, 2009 Notice of Allowance and Fee(s) Due issued in connection with co-pending U.S. Serial No. 11/234,879 **(Exhibit 24)**.

Items 1, 6, 9, 10, 15 and 16 were cited in connection with co-pending U.S. Serial No. 11/894,581, which names the same inventor as the subject application.

Items 2, 7, 11, 14, and 17 were cited in connection with co-pending U.S. Serial No. 10/512,518, which names the same inventor as the subject application.

Item 5 is a post-filing reference disclosed in connection with co-pending U.S. Serial No, 11/234,879, which names the same inventor as the subject application.

Items 8, 12, and 13 were cited in connection with co-pending U.S. Serial No. 11/648,769, which names the same inventor as the subject application.

Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003

Page 14 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

The Examiner is respectfully requested to make of record each item listed on Form PTO-1449 Substitute by initialing and dating the attached Form PTO-1449 Substitute, and returning a copy of the initialed and dated form to applicant's undersigned attorney.

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(b)(4), after the filing of a request for continued examination under 37 C.F.R. §1.113. Accordingly, no fee is required for filing this Supplemental Information Disclosure Statement.


Applicant : Silviu Itescu  
U.S. Serial No. : 10/693,480  
Filed : October 23, 2003

Page 15 of 15 - Communication in Response to February 3, 2009 Final Office Action and Supplemental Information Disclosure Statement as Submissions Under 37 C.F.R. §1.114(C) to the Accompanying Request for Continued Examination and Petition for Three-Month Extension of Time

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the total enclosed \$960.00, including \$405.00 for filing a Request for Continued Examination and \$555.00 for a three-month extension of time, is deemed necessary in connection with the filing of this Communication. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicant  
Customer No. 23432  
Cooper & Dunham LLP  
30 Rockefeller Plaza  
New York, New York 10112  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



John P. White  
Reg. No. 28,678

8/3/09  
Date

# **EXHIBIT A**

**COMMUNICATION IN RESPONSE TO  
FEBRUARY 3, 2009 FINAL OFFICE ACTION AND  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
AS SUBMISSIONS UNDER 37 C.F.R. §1.114(C)  
TO THE ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION  
AND PETITION FOR THREE-MONTH EXTENSION OF TIME**

**Filed: August 3, 2009**

**Applicants: Silviu Itescu  
Serial No.: 10/693,480  
Filed: October 23, 2003**